Jason Fontenot
Geen lopende functies
Vermogen: 68 544 $ op 30-04-2024
Profiel
Jason D.
Fontenot worked as the Chief Scientific Officer & Senior Vice President at Sangamo Therapeutics, Inc. from 2021 to 2024.
Prior to that, he was the Chief Scientific Officer at Immusoft Corp.
from 2018 to 2019 and the Head-Exploratory Research at Juno Therapeutics, Inc. from 2016 to 2018.
He earned a doctorate degree from the University of Washington.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-11-2023 | 136 270 ( 0.07% ) | 68 544 $ | 30-04-2024 |
Eerdere bekende functies van Jason Fontenot
| Bedrijven | Functie | Einde |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 02-01-2024 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Hoofd Techniek/Wetenschap/O&O | 01-03-2019 |
| JUNO THERAPEUTICS INC | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 |
Opleiding van Jason Fontenot
| University of Washington | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
